360 related articles for article (PubMed ID: 21143503)
1. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
Guest EJ; Rowland-Yeo K; Rostami-Hodjegan A; Tucker GT; Houston JB; Galetin A
Br J Clin Pharmacol; 2011 Jan; 71(1):72-87. PubMed ID: 21143503
[TBL] [Abstract][Full Text] [Related]
2. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.
Guest EJ; Aarons L; Houston JB; Rostami-Hodjegan A; Galetin A
Drug Metab Dispos; 2011 Feb; 39(2):170-3. PubMed ID: 21036951
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development.
Peters SA; Schroeder PE; Giri N; Dolgos H
Drug Metab Dispos; 2012 Aug; 40(8):1495-507. PubMed ID: 22566536
[TBL] [Abstract][Full Text] [Related]
4. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
[TBL] [Abstract][Full Text] [Related]
6. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
7.
Tseng E; Lin J; Strelevitz TJ; DaSilva E; Goosen TC; Obach RS
Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38408867
[TBL] [Abstract][Full Text] [Related]
8. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
9. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
10. Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator.
Kilford PJ; Chen KF; Crewe K; Gardner I; Hatley O; Ke AB; Neuhoff S; Zhang M; Rowland Yeo K
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):822-832. PubMed ID: 35445542
[TBL] [Abstract][Full Text] [Related]
11. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
Xu L; Chen Y; Pan Y; Skiles GL; Shou M
Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
[TBL] [Abstract][Full Text] [Related]
12. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different approaches to predict metabolic drug-drug interactions.
Einolf HJ
Xenobiotica; 2007; 37(10-11):1257-94. PubMed ID: 17968745
[TBL] [Abstract][Full Text] [Related]
14. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
Youdim KA; Zayed A; Dickins M; Phipps A; Griffiths M; Darekar A; Hyland R; Fahmi O; Hurst S; Plowchalk DR; Cook J; Guo F; Obach RS
Br J Clin Pharmacol; 2008 May; 65(5):680-92. PubMed ID: 18279465
[TBL] [Abstract][Full Text] [Related]
15. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
16. Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions.
Ly JQ; Messick K; Qin A; Takahashi RH; Choo EF
Mol Pharm; 2017 May; 14(5):1754-1759. PubMed ID: 28345929
[TBL] [Abstract][Full Text] [Related]
17. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
Iga K; Kiriyama A
J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.
Chu X; Chan GH; Houle R; Lin M; Yabut J; Fandozzi C
AAPS J; 2022 Mar; 24(3):45. PubMed ID: 35314909
[TBL] [Abstract][Full Text] [Related]
19. Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
Iga K
J Pharm Sci; 2015 Oct; 104(10):3565-77. PubMed ID: 26099559
[TBL] [Abstract][Full Text] [Related]
20. The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches.
Grime K; Ferguson DD; Riley RJ
Curr Drug Metab; 2010 Dec; 11(10):870-85. PubMed ID: 21208171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
